Evofem Biosciences Inc. [NASDAQ: EVFM] loss -4.81% on the last trading session, reaching $0.38 price per share at the time. The company report on December 16, 2021 that Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention.
Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion’s novel CCR5 antagonist, OB-002, in Evofem’s Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
The World Health Organization reported in 2020 that approximately 37.6 million people globally were living with HIV and an estimated 1.5 million individuals were newly diagnosed as HIV-positive. There are limited methods available to prevent transmission of HIV, and no products are approved to simultaneously prevent pregnancy, STIs and HIV.
Evofem Biosciences Inc. represents 154.26 million in outstanding shares, while the company has a total market value of $56.53 million with the latest information. EVFM stock price has been found in the range of $0.3719 to $0.3999.
If compared to the average trading volume of 3.23M shares, EVFM reached a trading volume of 3355089 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Evofem Biosciences Inc. [EVFM]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EVFM shares is $1.69 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EVFM stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Evofem Biosciences Inc. shares, keeping their opinion on the stock as Underweight, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on October 02, 2020, representing the official price target for Evofem Biosciences Inc. stock. Previously, the target price had yet another raise to $3, while Morgan Stanley analysts kept a Equal-Weight rating on EVFM stock.
The Average True Range (ATR) for Evofem Biosciences Inc. is set at 0.04, with the Price to Sales ratio for EVFM stock in the period of the last 12 months amounting to 11.78.
Trading performance analysis for EVFM stock
Evofem Biosciences Inc. [EVFM] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.31. With this latest performance, EVFM shares dropped by -10.79% in over the last four-week period, additionally sinking by -66.05% over the last 6 months – not to mention a drop of -84.96% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EVFM stock in for the last two-week period is set at 39.48, with the RSI for the last a single of trading hit 40.54, and the three-weeks RSI is set at 38.24 for Evofem Biosciences Inc. [EVFM]. The present Moving Average for the last 50 days of trading for this stock 0.5337, while it was recorded at 0.4173 for the last single week of trading, and 0.9671 for the last 200 days.
Evofem Biosciences Inc. [EVFM]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Evofem Biosciences Inc. [EVFM] shares currently have an operating margin of -23234.08 and a Gross Margin at -269.73. Evofem Biosciences Inc.’s Net Margin is presently recorded at -31907.85.
Return on Total Capital for EVFM is now -200.98, given the latest momentum, and Return on Invested Capital for the company is -590.20. Return on Equity for this stock declined to -1,675.90, with Return on Assets sitting at -205.85. When it comes to the capital structure of this company, Evofem Biosciences Inc. [EVFM] has a Total Debt to Total Equity ratio set at 6,380.10. Additionally, EVFM Total Debt to Total Capital is recorded at 98.46, with Total Debt to Total Assets ending up at 78.15. Long-Term Debt to Equity for the company is recorded at 2,319.30, with the Long-Term Debt to Total Capital now at 35.79.
Reflecting on the efficiency of the workforce at the company, Evofem Biosciences Inc. [EVFM] managed to generate an average of -$968,088 per employee. Receivables Turnover for the company is 0.45 with a Total Asset Turnover recorded at a value of 0.01.Evofem Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.50 and a Current Ratio set at 0.60.
An analysis of insider ownership at Evofem Biosciences Inc. [EVFM]
There are presently around $11 million, or 22.60% of EVFM stock, in the hands of institutional investors. The top three institutional holders of EVFM stocks are: VANGUARD GROUP INC with ownership of 7,009,858, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; D. E. SHAW & CO., INC., holding 4,502,323 shares of the stock with an approximate value of $1.81 million in EVFM stocks shares; and BLACKROCK INC., currently with $1.56 million in EVFM stock with ownership of nearly 13.913% of the company’s market capitalization.
Positions in Evofem Biosciences Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 25 institutional holders increased their position in Evofem Biosciences Inc. [NASDAQ:EVFM] by around 2,354,530 shares. Additionally, 40 investors decreased positions by around 11,740,813 shares, while 31 investors held positions by with 12,759,899 shares. The mentioned changes placed institutional holdings at 26,855,242 shares, according to the latest SEC report filing. EVFM stock had 12 new institutional investments in for a total of 1,332,527 shares, while 21 institutional investors sold positions of 4,033,599 shares during the same period.